Literature DB >> 6448112

Hepatitis B infection in institutionalized Down's syndrome inmates: a longitudinal study with five hepatitis B virus markers.

R A Hawkes, C R Boughton, D R Schroeter, R H Decker, L R Overby.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6448112      PMCID： PMC1538935     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


× No keyword cloud information.
  16 in total

1.  "e" Antigen, Dane particles, and serum DNA polymerase activity in HBsAg carriers.

Authors:  S H Hindman; C R Gravelle; B L Murphy; D W Bradley; W R Budge; J E Maynard
Journal:  Ann Intern Med       Date:  1976-10       Impact factor: 25.391

2.  e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants.

Authors:  K Okada; I Kamiyama; M Inomata; M Imai; Y Miyakawa
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

3.  A serum antigen (Australia antigen) in Down's syndrome, leukemia, and hepatitis.

Authors:  B S Blumberg; B J Gerstley; D A Hungerford; W T London; A I Sutnick
Journal:  Ann Intern Med       Date:  1967-05       Impact factor: 25.391

4.  Australia antigen and the immune response in human diseases.

Authors:  A I Sutnick
Journal:  J Allergy Clin Immunol       Date:  1974-01       Impact factor: 10.793

5.  Effects of host and environment on immunoglobulins in Down's syndrome.

Authors:  A I Sutnick; W T London; B S Blumberg
Journal:  Arch Intern Med       Date:  1969-12

6.  Antibody to hepatitis B core antigen. A sensitive indicator of hepatitis B virus replication.

Authors:  J H Hoofnagle; R J Gerety; L Y Ni; L F Barker
Journal:  N Engl J Med       Date:  1974-06-13       Impact factor: 91.245

7.  Hemagglutination assay for antigen and antibody associated with viral hepatitis.

Authors:  G N Vyas; N R Shulman
Journal:  Science       Date:  1970-10-16       Impact factor: 47.728

8.  Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure.

Authors:  H J Alter; L B Seeff; P M Kaplan; V J McAuliffe; E C Wright; J L Gerin; R H Purcell; P V Holland; H J Zimmerman
Journal:  N Engl J Med       Date:  1976-10-21       Impact factor: 91.245

9.  Antibody to hepatitis B core antigen.

Authors:  J H Hoffnagle; R J Gerety; L F Barker
Journal:  Am J Med Sci       Date:  1975 Jul-Aug       Impact factor: 2.378

10.  Hepatitis and hepatitis B-antigen in Greenland. II: Occurrence and interrelation of hepatitis B associated surface, core, and "e" antigen-antibody systems in a highly endemic area.

Authors:  P Skinhoj
Journal:  Am J Epidemiol       Date:  1977-02       Impact factor: 4.897
View more
  6 in total

1.  Primary sclerosing cholangitis preceding Crohn's disease in a child with Down's syndrome.

Authors:  P Vajro; S Cucchiara; A Vegnente; R Iorio; C de Silva; L Cipolletta; M A Bianco
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

2.  Hepatitis B virus infection in patients with rheumatic diseases.

Authors:  H Permin; J Aldershvile; J O Nielsen
Journal:  Ann Rheum Dis       Date:  1982-10       Impact factor: 19.103

3.  Immunological and virological investigations in Down's syndrome.

Authors:  G Fekete; G Kulcsár; P Dán; I Nász; D Schuler; M Dobos
Journal:  Eur J Pediatr       Date:  1982-02       Impact factor: 3.183

4.  Prevalence of hepatitis B virus infection among alcoholic patients with liver disease.

Authors:  M Orholm; J Aldershvile; U Tage-Jensen; P Schlichting; J O Nielsen; F Hardt; P Christoffersen
Journal:  J Clin Pathol       Date:  1981-12       Impact factor: 3.411

5.  Risk of hepatitis B in a ward for mentally retarded HBsAg carriers.

Authors:  J Eskola; J Keski-Oja; M Wilska; S Autio
Journal:  Infection       Date:  1986 Jul-Aug       Impact factor: 3.553

6.  Epidemiology of hepatitis B infection in institutionalized mentally retarded clients.

Authors:  S Lohiya; G Lohiya; S Caires
Journal:  Am J Public Health       Date:  1986-07       Impact factor: 9.308
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.